Fulltext

Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia

Wang HC 1 , Djajalaksana S 2 , Sharma L 3 , Theerakittikul T 4 , Lim HF 5 , Yoo KH 6 Show all authors , Yu-Lin AB 7 , Diaz DV 8 , Yang L 9 , Beekman MJHI 10

Affiliations 

  • 1 Department of Internal Medicine, National Taiwan University Hospital, Zhongzheng District, Taipei City 100, Taiwan
  • 2 Department of Pulmonology, University of Brawijaya-Dr. Saiful Anwar General Hospital, Kota Malang, Jawa Timur 65112, Indonesia
  • 3 Department of Pulmonology, KIMS Hospitals, Secunderabad, Telangana, India
  • 4 Department of Internal Medicine, Faculty of Medicine Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai 50200, Thailand
  • 5 National University Hospital, 5 Lower Kent Ridge Rd 119074, Singapore
  • 6 Division of Pulmonology and Allergy, Konkuk University Medical Center, Seoul, Korea 120-1 Neungdong-ro, Gwanjin-gu Seoul, 05030, South Korea
  • 7 Respiratory Unit, Dept of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur 56000, Malaysia
  • 8 Department of Pulmonary, Critical Care and Sleep Medicine, Lung Center of the Philippines, Quezon City, National Capital Region, 1100, Philippines
  • 9 Medical Affairs, AstraZeneca, Taiwan
  • 10 AstraZeneca, The Hague, the Netherlands
World Allergy Organ J, 2023 Oct;16(10):100823.
PMID: 37869560 DOI: 10.1016/j.waojou.2023.100823

Abstract

BACKGROUND: The extent of short-acting Beta-2-agonist (β2-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia.

METHODS: This cross-sectional study recruited patients (aged ≥12 years) with asthma from 8 Asian countries. Data on disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by practice type (primary or specialist care) and investigator-defined asthma severity (per Global Initiative for Asthma [GINA] 2017 recommendations). The association of SABA prescriptions with clinical outcomes was analyzed using multivariable regression models.

RESULTS: Overall, 3066 patients were analyzed, with a mean (standard deviation) age of 51.8 (16.7) years; of these patients, 2116 (69%) were female, 2517 (82.1%) had moderate-to-severe asthma and 2498 (81.5%) and 559 (18.2%) were treated in specialist and primary care, respectively. In total, 1423 (46.4%) patients had partly controlled/uncontrolled asthma, with 1149 (37.5%) patients experiencing ≥1 severe asthma exacerbation in the previous year. Overall, 800 (26.7%) patients were prescribed ≥3 SABA canisters in the previous year, which is regarded as overprescription and was associated with a significantly decreased odds of at least partly controlled asthma and increased incidence rates of severe exacerbations (P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications